Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting …
Omeros Corporation (NASDAQ:OMER) today announced that it has priced an underwritten public offering of 2,995,506 shares of its common stock at a per …
Wedbush analyst Liana Moussatos reiterated an Outperform rating on Omeros (NASDAQ:OMER) with a $52 price target, after the company announced positive data using OMS721, the …
MLV analyst George Zavoico assigned a Buy rating on Omeros (NASDAQ:OMER) with a $19 price target, as the company announced that the Center for …
In a research report issued today, Maxim Group analyst Jason Kolbert assigned a Buy rating on Omeros (NASDAQ:OMER) with a price target of …
In a research report sent to investors today, analyst Jason Kolbert of Maxim Group maintained a Buy rating on Omeros (NASDAQ:OMER) with a $24 price target, …
Maxim Group analyst Jason Kolbert provided an optimistic view on Omeros Corp. (OMER) heading into the company’s second-quarter earnings report, where it is …